Fig. 2: Tumors histopathological phenotype and immune composition. | npj Precision Oncology

Fig. 2: Tumors histopathological phenotype and immune composition.

From: Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies

Fig. 2

a An H&E and b CLIA IHC staining of estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2) was performed on both pre and on-treatment biopsies for each patient. mIHC was used to C reconstruct a region of each tumor showing epithelial cells (pan-CK) and various immune cells subtypes as indicated, d identification of immune cell population subset and density, and e determination of CD8+ T cell population characteristics based on expression of PD-1 and EOMES expression.

Back to article page